FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995474549> ?p ?o ?g. }

• W1995474549 endingPage "83" @default.
• W1995474549 startingPage "83" @default.
• W1995474549 abstract "Update on the use of rituximab for intractable rheumatoid arthritis R John LooneyUniversity of Rochester, Rochester, New York, USAAbstract: It has been 3 years since rituximab, a mouse x human chimeric anti-CD20 monoclonal antibody that selectively depleted B cells, was approved by the FDA for the treatment of moderate to severe rheumatoid arthritis (RA) with an inadequate response to anti-TNF therapies. Since approval rituximab has become a part of standard treatment, and additional data have become available on long-term efficacy and safety both from clinical trials and from post-marketing surveillance. In open long-term follow-up from clinical trials, patients treated with multiple courses of rituximab continued to respond in terms of signs and symptoms, and damage assessed radiographically was significantly inhibited. Moreover, the rate of serious infectious events was not increased as the number of courses increased. However, because of case reports of progressive multifocal leukoencephalopathy in patients treated with rituximab for non-malignant conditions, a black box warning has been added. Studies on the immunologic correlates of response to rituximab treatment including B cell subsets in peripheral blood and synovial biopsies are providing clues into how rituximab works for autoimmune disease. However, at this time we are not able to explain why some patients do not respond and cannot predict who will respond. Future challenges for the further development of rituximab for intractable RA will be discussed.Keywords: rheumatoid arthritis, rituximab, B cells, immunocompetency" @default.
• W1995474549 created "2016-06-24" @default.
• W1995474549 creator A5018230660 @default.
• W1995474549 date "2009-07-01" @default.
• W1995474549 modified "2023-09-30" @default.
• W1995474549 title "Update on the use of rituximab for intractable rheumatoid arthritis" @default.
• W1995474549 cites W1576993812 @default.
• W1995474549 cites W1603245933 @default.
• W1995474549 cites W1675831178 @default.
• W1995474549 cites W1722080576 @default.
• W1995474549 cites W1922855985 @default.
• W1995474549 cites W1965723104 @default.
• W1995474549 cites W1968241220 @default.
• W1995474549 cites W1978238469 @default.
• W1995474549 cites W1981941163 @default.
• W1995474549 cites W1983880965 @default.
• W1995474549 cites W1985380203 @default.
• W1995474549 cites W1993847760 @default.
• W1995474549 cites W1995386393 @default.
• W1995474549 cites W1995588846 @default.
• W1995474549 cites W1998618256 @default.
• W1995474549 cites W2001107080 @default.
• W1995474549 cites W2001313261 @default.
• W1995474549 cites W2001710332 @default.
• W1995474549 cites W2003687800 @default.
• W1995474549 cites W2004348520 @default.
• W1995474549 cites W2008688804 @default.
• W1995474549 cites W2011555570 @default.
• W1995474549 cites W2013117089 @default.
• W1995474549 cites W2020074258 @default.
• W1995474549 cites W2021878902 @default.
• W1995474549 cites W2022669864 @default.
• W1995474549 cites W2023442831 @default.
• W1995474549 cites W2024644107 @default.
• W1995474549 cites W2028453745 @default.
• W1995474549 cites W2038783844 @default.
• W1995474549 cites W2039110250 @default.
• W1995474549 cites W2040876247 @default.
• W1995474549 cites W2041237232 @default.
• W1995474549 cites W2043104155 @default.
• W1995474549 cites W2046900942 @default.
• W1995474549 cites W2059125686 @default.
• W1995474549 cites W2060467993 @default.
• W1995474549 cites W2061698567 @default.
• W1995474549 cites W2061709866 @default.
• W1995474549 cites W2063248903 @default.
• W1995474549 cites W2075763185 @default.
• W1995474549 cites W2076971074 @default.
• W1995474549 cites W2077158310 @default.
• W1995474549 cites W2077286174 @default.
• W1995474549 cites W2077882848 @default.
• W1995474549 cites W2085997970 @default.
• W1995474549 cites W2086080135 @default.
• W1995474549 cites W2087830073 @default.
• W1995474549 cites W2088205067 @default.
• W1995474549 cites W2089016290 @default.
• W1995474549 cites W2097025094 @default.
• W1995474549 cites W2097805045 @default.
• W1995474549 cites W2106197507 @default.
• W1995474549 cites W2107741982 @default.
• W1995474549 cites W2108787411 @default.
• W1995474549 cites W2109557768 @default.
• W1995474549 cites W2110882920 @default.
• W1995474549 cites W2118994799 @default.
• W1995474549 cites W2122176733 @default.
• W1995474549 cites W2122507029 @default.
• W1995474549 cites W2123531724 @default.
• W1995474549 cites W2124707938 @default.
• W1995474549 cites W2126200942 @default.
• W1995474549 cites W2127014397 @default.
• W1995474549 cites W2130713463 @default.
• W1995474549 cites W2133741523 @default.
• W1995474549 cites W2134811804 @default.
• W1995474549 cites W2136023353 @default.
• W1995474549 cites W2138565878 @default.
• W1995474549 cites W2141825494 @default.
• W1995474549 cites W2142415495 @default.
• W1995474549 cites W2144047233 @default.
• W1995474549 cites W2147330138 @default.
• W1995474549 cites W2150932450 @default.
• W1995474549 cites W2151703174 @default.
• W1995474549 cites W2152808869 @default.
• W1995474549 cites W2156180689 @default.
• W1995474549 cites W2156639920 @default.
• W1995474549 cites W2157130851 @default.
• W1995474549 cites W2161758234 @default.
• W1995474549 cites W2167077459 @default.
• W1995474549 cites W2169082675 @default.
• W1995474549 cites W2182567877 @default.
• W1995474549 cites W2184433791 @default.
• W1995474549 cites W2264923623 @default.
• W1995474549 cites W25794465 @default.
• W1995474549 cites W2588368793 @default.
• W1995474549 doi "https://doi.org/10.2147/oarrr.s4968" @default.
• W1995474549 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5074725" @default.
• W1995474549 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27789983" @default.
• W1995474549 hasPublicationYear "2009" @default.
• W1995474549 type Work @default.

• next